Meta-analysisindependent cross-checkfull text checked★ key study I-CHM-01 in-depth review
Chemotherapy after breast-cancer surgery reduces deaths by about a third
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Overview
EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5
In 123 trials with 100,000 women, modern regimens cut breast-cancer deaths by about one-third, and overall deaths fell too.
Does the study support the specific claim? No · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Compare chemotherapy regimens and no chemotherapy.
- How was the study done?
IPD meta-analysis of RCTs.
- How many people, animals or samples were studied?
~100,000 women.
- What was actually found?
~1/3 lower breast-cancer mortality.
- How large was the observed effect?
RR 0.64-0.78 vs none.
- What do the results mean in everyday life?
For many women, chemotherapy substantially raises the chance of survival.
- What are the study's limitations?
Trials versus no chemotherapy are old (median start 1986); a small excess of non-breast-cancer deaths (e.g. heart, leukaemia) occurred; benefit is small when baseline risk is low.
- What does it say about Elawady's specific claim?
Contradicts claims that chemotherapy is useless.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Individual benefit without risk assessment.
Scientific in-depth review
1. Full reference
- Authors
- EBCTCG
- Journal
- Lancet
- Year
- 2012
- Identifier
- PMID 22152853 DOI 10.1016/S0140-6736(11)61625-5
- Verification
- verified – PubMed esummary + efetch 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- full text
- Conflicts of interest and funding
EBCTCG core funding: Cancer Research UK, British Heart Foundation, UK Medical Research Council (funders no role). COI: external writing-committee members declared patents on genomic grade index/recurrence score (MP), honoraria from Genomic Health (KA), and honoraria/consultancy from 3-7 pharmaceutical companies (JB, ADL, KA, KP, MP); internal CTSU members none (staff policy excludes honoraria). Industry sponsorship of individual trials listed in webappendix.
2. Research question
Efficacy of adjuvant chemotherapy regimens, including polychemotherapy vs none.
3. Study design and population
- Study design
- Meta-analysis – Collaborative individual-patient-data meta-analyses (EBCTCG) of randomised adjuvant chemotherapy trials, log-rank methods stratified by trial, age, ER and nodal status
- Population
Women with early breast cancer
- Country
International
- Period
Trials begun 1973-2003; IPD collected 2005-2010; polychemotherapy-vs-none trials begun 1973-96 (median start 1986)
- Sample size
123 trials, ~100,000 women: taxane+anthracycline vs non-taxane (33 trials, n~44,000-45,000; 3 trials with n~7000 unavailable), anthracycline vs CMF (20 trials, n~18,000), higher vs lower anthracycline dose (6 trials, n~7000), polychemotherapy vs none (64 trials, n~32,000)
- Inclusion and exclusion criteria
All randomised trials begun 1973-2003 of the four comparisons; trials of stem-cell-supported high-dose chemotherapy or of dose-density only excluded; main analyses include >=99% of relevant patients in closed trials (except 3 unreported taxane trials)
4. Methods and endpoints
- Exposure / intervention
Taxane/anthracycline/CMF regimens
- Comparator
No chemotherapy or other regimens
- Endpoints
Breast cancer mortality; overall mortality
- Statistical methods
Stratified log-rank event rate ratios (RR = exp((O-E)/V)) with SE; breast cancer mortality derived as overall minus non-recurrence mortality; 2p two-sided; subgroup analyses with stated reliability caveats (overall chi-square thresholds)
5. Actual results
- Results
Taxane added to fixed anthracycline control (unconfounded trials): breast cancer mortality RR 0.86 (SE 0.04), 8-year breast cancer mortality 21.1% vs 23.9%; taxane vs ~doubled non-taxane chemotherapy: RR 0.94 (SE 0.06), not significant. All taxane trials (n=44,000): breast cancer mortality RR 0.87, overall mortality RR 0.89 (SE 0.03). CAF/CEF vs standard CMF: breast cancer mortality RR 0.78 (SE 0.06); standard 4AC vs standard CMF RR 0.98 (SE 0.05). Versus no chemotherapy: any anthracycline regimen (n=8500) breast cancer mortality RR 0.79 (SE 0.04), other (non-breast-cancer) mortality RR 1.20 (SE 0.10), overall mortality RR 0.84 (SE 0.03); CMF (n=5000) breast cancer mortality RR 0.76 (SE 0.05), other mortality RR 1.24 (SE 0.12), overall mortality RR 0.84 (SE 0.05); CAF RR 0.64 (SE 0.09), standard 4AC RR 0.78 (SE 0.09). Proportional reductions largely independent of age (<=70), nodal status, tumour size/grade, ER status, tamoxifen use. Cardiac mortality RR for anthracycline regimens 1.56 (SE 0.24) vs CMF or nil. Authors estimate more effective regimens reduce 10-year breast cancer mortality by about one-third vs no chemotherapy. Results are given as RR with SE (95% CIs mainly in figures).
- Absolute risks
Unconfounded taxane trials: 8-year breast cancer mortality 21.1% vs 23.9% (absolute gain 2.8%, SE 0.9), similar gain for overall mortality. 1-year mortality without recurrence (age <70): 59/19,477 (0.3%) taxane+anthracycline vs 40/19,386 (0.2%) anthracycline controls. AML deaths without recurrence e.g. 11 vs 1 (taxane trials), 8 vs 0 (anthracycline vs nil); paclitaxel 225 mg/m2 7/1531 (0.5%), CAF 5/2638 and 2/1177 (0.2%). Other absolute 10-year gains in figures/webappendix only.
- Authors' conclusion
Some taxane-plus-anthracycline or higher-cumulative-dose anthracycline regimens reduce breast cancer mortality by about one-third, largely independently of age and available tumour characteristics; 10-year overall mortality differences parallel breast cancer mortality differences despite toxicities. Absolute gain depends on absolute risk; in low-risk ER-positive disease on endocrine therapy the absolute gain cannot be large and patients not helped are harmed by toxicity.
6. Strengths
- Individual patient data from nearly all randomised trials (>=99% of patients in closed trials)
- Randomised comparisons with intention-to-treat log-rank analysis
- Overall and non-breast-cancer mortality reported, so harms are quantified
- Pre-stated cautions on subgroup reliability
7. Weaknesses
- Chemotherapy-vs-none trials are old (median start 1986), half without endocrine therapy, suboptimal supportive care
- 3 taxane trials (n~7000) unavailable; taxane follow-up short (mostly <=8 years)
- Comparisons between regimens are largely indirect and confounded by other drug differences
- Few women >70 or with small well-differentiated (luminal-A) tumours; no genomic/Ki-67 data
- Some trials did not report causes of death; non-breast-cancer mortality excess (RR 1.20-1.24) in old trials
- No formal per-trial risk-of-bias assessment reported in main text; effect estimates given as RR with SE
8. Risk of bias
- Orienting tool
- AMSTAR 2 (adapted to collaborative IPD meta-analysis)
- Type of assessment
- structured assessment based on the full text by a single reviewer (no formal double review)
- Full formal assessment
- no
- Overall risk of bias
- low
- Rationale
Risk of bias in the main conclusions is low; a formal AMSTAR 2 confidence rating would be downgraded for unreported protocol registration and absent formal per-trial RoB assessment, which matters little for randomised IPD of near-complete trial sets. Single-reviewer structured judgement from the full text; a complete formal assessment requires two independent reviewers and the review/study protocol.
| Domain | Judgement | Rationale |
|---|---|---|
| Item 1 PICO | low | Comparisons, populations and outcomes clearly defined. |
| Item 2 protocol (critical) | some concerns | Methods follow previously published EBCTCG procedures; no registered protocol cited in the text. |
| Item 4 comprehensive search (critical) | some concerns | Trial identification 'as in previous EBCTCG reports' with trialist collaboration; search details not given in this paper, but near-complete trial coverage stated. |
| Items 5/6 duplicate selection/extraction | low | Central IPD collection and data checking by the Secretariat with trialist verification. |
| Item 7 excluded studies (critical) | some concerns | Exclusion categories stated (stem-cell, dose-density) and 3 missing taxane trials shown in webappendix; no full exclusion list in main text. |
| Item 9 risk of bias of included RCTs (critical) | some concerns | No formal RoB tool reported; IPD with randomised, stratified ITT analysis reduces but does not eliminate concerns (e.g. unreported causes of death). |
| Item 11 appropriate synthesis (critical) | low | Stratified log-rank IPD methods appropriate; indirect comparisons acknowledged. |
| Item 13 RoB considered in interpretation (critical) | low | Authors discuss confounded comparisons, chance in subgroups and old trial conditions. |
| Item 15 publication bias (critical) | low | IPD from virtually all trials minimises publication bias; 3 unreported taxane trials noted. |
| Item 16 conflicts of interest | low | Funding and COI declared; trial sponsorship listed. |
Full-text review (25 October 2026): Added trial counts per comparison, trial period, 3 missing taxane trials, overall-mortality RR 0.84 vs no chemotherapy, non-breast-cancer mortality RR 1.20/1.24, cardiac mortality RR 1.56, AML deaths and 1-year non-recurrence mortality (0.3% vs 0.2%), 8-year absolute taxane gain 2.8%, external-author pharma/patent COI; results are RR with SE (not 95% CI). AMSTAR 2 domains documented; overall bias unchanged (low).
9. Assessment of the statistical interpretation
Randomised IPD evidence: proportional breast cancer mortality reductions of ~20-36% depending on regimen, with overall mortality also reduced (RR 0.84 vs no chemotherapy) despite a measurable excess of non-breast-cancer deaths (RR 1.20-1.24 in old trials; cardiac RR 1.56; few AML deaths). Net benefit at population level; absolute benefit scales with baseline risk and is small in low-risk disease.
10. Relevance to the specific claim
Quantifies the benefit side omitted by the archive and denied in Elawady's videos.
11. Independent contrary findings
Low-risk patients gain little (authors).
12. Transferability to Germany and Europe
High.
13. Overall methodological judgement
Highest-level evidence that adjuvant chemotherapy reduces breast cancer and all-cause mortality in early breast cancer; the full text also documents real but small treatment-related mortality, which the net overall-mortality reduction outweighs on average.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | low |
| Precision of results | high |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Who can safely omit chemotherapy (genomic tests: MINDACT, TAILORx, RxPONDER); long-term late toxicity beyond 10 years.
15. Linked fact checks
- The archive's 19 chemo/radiation studies are presented on the homepage as 'scientific studies confirming what Dr. Diaa proposed'; the harm-only study selection implies that the harms of chemotherapy and radiotherapy outweigh their benefits. – Studies contradicting or limiting the claim
- Chemotherapy and tumour-removal surgery do not address root causes; the body will reactivate its 'defensive plan' elsewhere, so these treatments should be avoided. – Studies contradicting or limiting the claim
- Cancer patients should not take chemotherapy, radiotherapy or biological therapy (or should stop them) and follow the Tayebat system instead; 'we are against the word medicine'. – Studies contradicting or limiting the claim
- Oncology only buys time: 'survival rates' are meaningless, patients die during treatment, and early diagnosis only makes you 'die early'. – Studies contradicting or limiting the claim
- The system's life method is 'zero medicine': a life without any medicines at all. – Studies contradicting or limiting the claim